The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...
In a randomized trial, ART intensification by doubling the dolutegravir dosage in people with HIV stably suppressed on ...
On the left is integrase in its “intasome” structure of four identical four-part complexes (pink) that connect to create one 16-part complex that locks around viral DNA (blue). On the right is ...
Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...
CD8 T lymphocytes from immunologically stable HIV-1-infected secrete a soluble factor — termed CAF —, which suppresses HIV-1 replication, but the exact identity of CAF has been unclear. In September ...
I see that ViroLogic now offers information on the replicative capacity of patient virus, alongside information on its genotypic and phenotypic resistance profile. How should we use this information ...
A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some HIV-positive individuals, known as viremic non-progressors (VNPs), to avoid ...
HIV-1 infection, in combination with other antiretrovirals, in treatment-experienced adults with evidence of viral replication and HIV-1 strains resistant to multiple antiretrovirals. Raltegravir ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results